National Pharmaceuticals Corporation Appoints a New CEO and Sets a New Course
MIAMI, FLORIDA, Dec. 8, 2010 (Marketwire) -- National Pharmaceuticals Corporation (PINK SHEETS:NFRM) is pleased to announce the appointment of Elaine Affleck as its new President and CEO. Ms. Affleck has been a Board Member of NFRM.PK. Ms. Affleck has served on several other boards in the past and brings her extensive business and accounting knowledge in assisting NFRM.PK to implement its future business plans.
NFRM.PK also is pleased to announce that it has entered into a Letter of Intent (LOI) to acquire a certain Proprietary Robotic technology from Excelco Systems International. Most robotic applications are singular processes where a single arm of Robot applies a pre-determined task. Most of the public can relate to this by watching the singular Robot applying welding on the car manufacturing assembly-lines. Excelco has developed a multi arm Robotic Technology that can easily do multiple applications at the same time therefore increasing efficiencies of any type of assembly lines or packaged goods manufacturing for Medical, Pharmaceutical, Food and many other industries. More details of the Robotic Technology will be provide once the LOI becomes a definitive Agreement.
National Pharmaceuticals is set to be recognized as a market leader committed to reducing supply chain costs by application of Robotic Automation to medical, institutional, Food and packaging industries.
Safe Harbor Statement: This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's contract manufacturers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
National Pharmaceuticals Corporation (954) 903-1967
Source: Marketwire Canada (December 8, 2010 - 4:59 PM EST)
News by QuoteMedia
www.quotemedia.com
AI
